

MARKET DISRUPTION BRIEF

Pfizer plant: Rocky Mount, NC (reviewed November 13)

The Pfizer facility in Rocky Mount, North Carolina was **damaged by a tornado** on July 19.

There are no new updates as of 11/13/2023

Vizient resources available

- **Supply Chain Disruption Report** – which includes a market analysis of the subset of products provided by Pfizer in their customer letter with less than 3 months of inventory in the distribution channels. The report also contains available mitigation strategies for several of the affected products if needed due to the potential supply constraint.
- **Vizient Drug Shortage Alerts** – information compiled by the University of Utah (authors of the ASHP drug shortage list) with shortage information and contract-specific information. If any drug shortages result from the impacted plant, the specific information will be provided in the alerts.
- **Vizient Mitigation Strategy Library** – several of the products highlighted by Pfizer in their customer letter have ongoing shortages. As a result, many have mitigation strategies available. Refer to the Supply Chain Disruption Report for those with mitigation strategies. For a full list of available mitigation strategies refer to the library. The mitigation strategies are designed to provide clinical and operational recommendations to mitigate a shortage of the product.

Current conditions

Updates as of September 25th: In a **press release** on September 25th, Pfizer noted the resumption of production at the majority of their manufacturing lines at Rocky Mount. Additionally, Pfizer noted the launch of one manufacturing line in the site's new sterile injectable manufacturing area, referred to as R3. There are approximately 13 medicines in production on the lines that have restarted, including products that are only available through Pfizer's emergency ordering process. The first shipments to distribution centers of these medicines are anticipated in Q4 2023. The emergency ordering process will remain in effect for the 14 previously identified medicine presentations; however, when inventory levels allow, Pfizer will also intermittently distribute additional inventory not necessary for maintain the emergency ordering process to wholesalers and distributors. Pfizer estimates the impact of the tornado will affect the supply of medicines from the Rocky Mount facility until at least mid-2024. A new warehouse has also been secured as a temporary replacement to the HiRise warehouse, which was most affected by the tornado. The new warehouse will store non-production related materials, such as packaging components.

Vizient continues to meet with Pfizer leadership monthly and ad-hoc as new developments become available. Pfizer colleagues and have returned to the Pfizer Rocky Mount site, and recovery is well underway to address the damage caused by the tornado. In the interim, Pfizer has secured additional warehousing to meet interim storage needs, while the work to rebuild the damaged facility continues. Pfizer continues to accelerate manufacturing restart activities with a clear line of sight for resuming product filling and subsequent product delivery to the market. Manufacturing of sterile injectable products is a complex and highly regulated process governed by contemporary Good Manufacturing Practices (GMPs). As such, Pfizer continues to communicate with the FDA and appropriate governmental bodies accordingly as the Pfizer Rocky Mount plant continues its operational ramp up for restart.

Frequently asked questions

Was Novaplus Enhanced Supply (NES) or NES Reserve inventory housed at the Rocky Mount warehouse?

- No, neither NES or NES Reserve inventory was housed at the Rocky Mount facility.

It was noted that raw materials and active pharmaceutical ingredients (APIs) were stored at the Rocky Mount warehouse, will this have an impact on future production of certain medications?

- Currently Pfizer does not anticipate impact as new orders for raw materials and API continue to be received as those orders are placed months to years in advance.

Rocky Mount facility specifics

According to **Pfizer's website**, the Rocky Mount plant is one of the largest sterile injectable facilities in the world, with more than 1.4 million square feet of facility space on 250 acres in Eastern North Carolina. **Nearly 25% of Pfizer's sterile injectables, which is approximately 8% of all sterile injectables used in the US hospitals are manufactured at this plant.** Pfizer manufactures products across many categories at this plant including anesthesia, analgesia, therapeutics, anti-infectives, and neuromuscular blockers.



To learn more, please contact:
pharmacyquestions@vizientinc.com

As the nation's largest member-driven health care performance improvement company, Vizient provides solutions and services that empower health care providers to deliver high-value care by aligning cost, quality and market performance. With analytics, advisory services and a robust sourcing portfolio, we help members improve patient outcomes and lower costs.

FDA statement

Information was provided in an [FDA statement document](#) on July 21, 2023, which stated “we do not expect there to be any immediate significant impacts on supply given the products are currently at hospitals and in the distribution system, but this is a dynamic situation and FDA staff are in frequent communication with Pfizer and other manufacturers.”

Pfizer communications

Pfizer communicated on the Vizient Assurance update call July 21st that the production facilities at Rocky Mount (Rocky 1 and Rocky 2) are intact and were undamaged by the tornado and they are continuing to assess the overall impact. Pfizer and government agencies have been on-site to assess the integrity of the production facilities and the warehouse of the larger manufacturer facility. Pfizer also clarified on the Vizient Assurance call that propofol and vancomycin are not produced at the Rocky Mount facility.

Information was provided by Pfizer in customer letters on July 21, August 3, August 24, August 28 and September 25, 2023:

- Following an initial assessment, there does not appear to be any major damage to the production facilities.
- The customer letter and [Pfizer press release](#) indicates that the primary impact of the tornado was to the warehouse facility, which stores raw materials, packaging supplies, and finished medicines awaiting release by quality assurance.
- Pfizer is exploring alternative manufacturing locations for production across the US and internationally, including across the company's partner network.
- Refer to [Appendix 1](#) for an identified subset of Rocky Mount products that may experience continued or new supply disruptions in the near-term due to this weather event. The subset is based on the Pfizer market share and inventory levels of less than 3 months across our Pfizer distribution centers and the wholesale chain.
- Pfizer Hospital will continue to fill orders of products for which we have inventory in the distribution chain at 100 percent of historical levels.
- Out of an abundance of caution due to the weather event, allocations were placed on the entire Pfizer Hospital portfolio. The allocations on non-Rocky Mount products will be lifted.
- Out of an abundance of caution, Pfizer announced in an August 3rd customer letter that due to their high medical need, a small subset of Rocky Mount presentations (refer to [Appendix 2](#)) will be available through Pfizer's emergency order process via direct shipment from Pfizer only, effective immediately and until further notice. All products not included in this list and available in the distribution chain, customers will continue to see orders fulfilled consistent with 100% of historical level.
- Out of an abundance of caution, Pfizer announced in an August 24th customer letter that two additional presentations (refer to [Appendix 2](#)) will be available through Pfizer's emergency order process via direct shipment from Pfizer only, effective August 23rd and until further notice.
- Pfizer announced in an August 28th customer letter that the site reopened August 7th and announced a release to distribution centers of product that was not impacted by the tornado. This product was cleared for release through stringent quality assurance processes. Pfizer is also working on knowledge and documentation transfers for product manufacturing (tech transfers) to other sterile injectable sites in the network to accelerate the supply of its products. This includes working with regulatory bodies to ensure compliance and to obtain approvals. Production at the facility is expected to restart by Q4 2023.
- Pfizer announced in a September 25th [press release](#) the resumption of production at the majority of their manufacturing lines at Rocky Mount. Additionally, Pfizer noted the launch of one manufacturing line in the site's new sterile injectable manufacturing area, referred to as R3. There are approximately 13 medicines in production on the lines that have restarted, including products that are only available through Pfizer's emergency ordering process. The first shipments to distribution centers of these medicines are anticipated in Q4 2023. The emergency ordering process will remain in effect for the 14 previously identified medicine presentations; however, when inventory levels allow, Pfizer will also intermittently distribute additional inventory not necessary for maintain the emergency ordering process to wholesalers and distributors. Pfizer estimates the impact of the tornado will affect the supply of medicines from the Rocky Mount facility until at least mid-2024. A new warehouse has also been secured as a temporary replacement to the HiRise warehouse, which was most affected by the tornado. The new warehouse will store non-production related materials, such as packaging components.
- At this time, customers can leverage the “Supply Status” column of our [Availability Report](#) on www.PfizerHospitalUS.com to understand the latest inventory status of Pfizer's sterile injectable products. Please note that next delivery and estimated recovery dates are not accurate for Rocky Mount products until further notice.
- Please note that Pfizer does not produce COMIRNATY® (COVID-19 Vaccine, mRNA), or PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets) at the site. We also do not produce sterile injectable oncology products, SOLU-CORTEF® (hydrocortisone sodium succinate for injection, USP), SOLU-MEDROL® (methylprednisolone sodium succinate for injection, USP), or BICILLIN® L-A (penicillin G benzathine injectable suspension) at the site.

While the Rocky Mount facility is closed Pfizer encourages procurement of product normally except for products listed in [Appendix 2](#) as the assessment of the facility continues.

Vizient response

Vizient has also further analyzed the NDCs provided in [Appendix 1](#) of the Pfizer customer letter to understand the market share of each of these products nationally and amongst its membership. Our Center for Pharmacy Practice Excellence team has identified products manufactured at the Rocky Mount plant that were already experiencing supply challenges, such as electrolytes, analgesic agents and opioids, to understand how this event may further impact providers and encourages inventory stewardship by hospitals. Multiple [mitigation strategies](#) as well as 503b alternatives have been utilized to manage these ongoing shortages. The market analysis and available mitigation strategies can be found in the [Vizient Supply Chain Disruption Report](#).

Vizient is actively working with various industry stakeholders including supplier and distributor partners, and [End Drug Shortages Alliance](#) to identify the current potential impact as a result of this natural disaster.

- Vizient has activated the pharmacy rapid response team, which includes clinical, sourcing, analytics, government relations, communications and others to fully assess the potential market impact. The list of affected medications has not yet been made available by Pfizer.
- Vizient is communicating with Pfizer to assess the potential supply constraints resulting from any production delay as a result of the tornado. Timelines and impact on current and future production at the facility are unknown at this time.
- Vizient is working with alternate manufacturers of any impacted products to assess their ability to supply and capabilities to increase production if necessary.
- Vizient has communicated with pharmacy wholesalers to advocate and advise for pre-emptive management of any essential medications with anticipated impact.
- Vizient has worked with pharmacy wholesalers to manage orders at 120% of utilization on all Novaplus [essential medications](#).
- [Vizient has several mitigation strategies](#) available for review if needed for any future issues.

Novaplus Enhanced Supply

As an added clarification to the information provided in [Appendix 2](#), please continue to request the following **10 NES products** through Vizient Advanced Access Hub (VAAH) (<https://advancedaccess.vizientinc.com/>).

Available through Vizient Advanced Access Hub (VAAH)

NDC	NDC Description
00409114102	Sodium chloride 23.4% 100 mL
00409555502	Sodium bicarbonate 4.2% 5 mL
00409662514	SODIUM BICARBONATE 8.4% VIAL
00409234401	DOBUTAMINE 250 mg/20 mL VIAL
00409234402	DOBUTAMINE 250 mg/20 mL VIAL
00409582001	dopamine HCl 200 mg/5mL 5ML
00409910420	dopamine HCl 400 mg/10 mL 10 mL
00409329451	Potassium acetate 100 mEq/50 mL
00409729501	Potassium phosphates 45 mM P/15 mL
00409329905	Sodium acetate 100 mEq/50 mL

The remaining **4 products** below are not in the NES program and can be requested directly through Pfizer's emergency procurement process.

Available directly through Pfizer's Emergency Procurement Process

NDC	NDC Description
00409491034	Atropine Sulfate Injection, USP (Adult) 0.5 mg/5 mL LifeShield™ ABBOJECT™ Syringe
00409409201	Copper (cupric chloride injection, USP)
00409177510	Dextrose Injection 25%, USP (For Infant Use) 2.5 g/10 mL (250 mg/mL) ANSYR™ Plastic Syringe
00409915701	Vitamin K1 Neonate (phytonadione injectable emulsion, USP) 1 mg/0.5 mL (2 mg/mL) Glass Ampoule

Providers call to action

- Hospitals and health systems are advised to activate their internal drug shortage committees and inform the appropriate multidisciplinary stakeholders of the impacted Pfizer facility. Regularly scheduled meetings should continue until resolution of any potential supply constraints.
- Vizient encourages providers to utilize principles of [Drug Shortage Stewardship](#) to manage demand and limit drug shortage impact.
- Notify C-Suite level executives of the impacted Pfizer facility to ensure appropriate communication of potential supply constraints to the local media and associated medical boards.
- Each hospital and health system should evaluate and ensure all inventory counts are accurate and up to date.
- Notify pharmacy buyers and inventory managers of any potential allocation implementation by the wholesalers. When implemented, ensure the allocations are accurate based on historical orders and maintain frequent communication with wholesaler representatives to triage any issues.
- Based on the information provided on Pfizer's website – review, revise, and prepare to implement mitigation strategies available for medications in the following classes anesthesia, analgesia, anti-infectives, and neuromuscular blockers.
- Review the available Vizient mitigation strategy library to evaluate any potential mitigation strategies which may need to be potentially updated.
- Regularly communicate with neighboring hospitals and health systems to ensure medications are available to the local population, if any potential supply constraints do occur.

Distributor actions

AmerisourceBergen

- All Pfizer injectables have been placed on a 100% allocation
- All Pfizer non-injectables have been placed on a 250% allocation
- All Novaplus Y-labeled items have been placed on a 120% allocation

Cardinal

- All Pfizer injectables have been placed on a 100% allocation
- All Novaplus Y-labeled items have been placed on a 125% allocation

McKesson

- All Pfizer injectables have been placed on a 100% allocation
- All Novaplus Y-labeled items have been placed on a 120% allocation

Morris & Dickson

- All Pfizer injectables have been placed on a 100% allocation
- All Pfizer non-injectables have been placed on an allocation of 3-4 purchase units per day
- All Novaplus Y-labeled items have been placed on a 125% allocation

Pfizer Supply Continuity Support

For your supply needs, including order fulfillment/status and allocation requests, please contact the Pfizer's Supply Continuity Team.

The Supply Continuity Team can be contacted between 7 a.m. and 5 p.m. (CT) at 1-844-646-4398 (select option 1 [Customer], then option 3 [Supply Continuity Team]). For medical inquiries, please contact Pfizer Medical Information at 1-800-438-1985.

In a customer letter sent on July 21st Pfizer stated: "In an abundance of caution while we complete our assessment, all Pfizer Hospital sterile injectable products have been put on allocation at a minimum of 100% of historical purchases. These allocations are in place in both direct order channels and at the wholesaler. We will lift or modify these allocations as soon as we learn more about the supply impact on specific products manufactured at Rocky Mount as a result of this event."

Appendix 1. Pfizer Hospital Rocky Mount Products with Less Than 3 Months' Inventory in the Distribution Chain

NDC	Product Description
00409-3308-03	Acetylcysteine Solution, USP 6 g/30 mL (200 mg/mL) Multiple Dose Glass Teartop Vial
00409-4346-73	Aminocaproic Acid Injection, USP 5 g/20 mL (250 mg/mL) Single Dose Plastic Fliptop Vial
00409-5921-01	Aminophylline Injection, USP 250 mg/10 mL (25 mg/mL) Single Dose Glass Fliptop Vial
00409-1630-10	Atropine Sulfate Injection, USP (Adult) 1 mg/10 mL (0.1 mg/mL) ANSYR™ Plastic Syringe
00409-4911-34	Atropine Sulfate Injection, USP (Adult) 1 mg/10 mL (0.1 mg/mL) LifeShield™ ABBOJECT™ Glass Syringe (20 G x 1 1/2")
00409-1966-12	Bacteriostatic 0.9% Sodium Chloride Injection, USP 10 mL Multiple Dose LifeShield™ Plastic Fliptop Vial
00409-3613-01	Bupivacaine 0.75% Spinal (bupivacaine in dextrose injection, USP) 15 mg/2 mL (7.5 mg/mL) Glass Ampoule
00409-1623-01	Butorphanol Tartrate Injection, USP, CIV 1 mg/mL Single Dose Glass Fliptop Vial
00409-1626-01	Butorphanol Tartrate Injection, USP, CIV 2 mg/mL Single Dose Glass Fliptop Vial
00409-1626-02	Butorphanol Tartrate Injection, USP, CIV 4 mg/2 mL (2 mg/mL) Single Dose Glass Fliptop Vial
00409-1631-10	Calcium Chloride Injection, USP 1 g/10 mL (100 mg/mL) ANSYR™ Plastic Syringe
00409-4928-34	Calcium Chloride Injection, USP 1 g/10 mL (100 mg/mL) LifeShield™ ABBOJECT™ Glass Syringe (20 G x 1 1/2")
00409-1775-10	Dextrose Injection 25%, USP (For Infant Use) 2.5 g/10 mL (250 mg/mL) ANSYR™ Plastic Syringe
00409-7517-16	Dextrose Injection 50%, USP 25 g/50 mL (500 mg/mL) ANSYR™ II Plastic Syringe (side/side)
00409-4902-34	Dextrose Injection 50%, USP 25 g/50 mL (500 mg/mL) LifeShield™ ABBOJECT™ Glass Syringe (18 G x 1 1/2")
00409-6648-02	Dextrose Injection 50%, USP 25 g/50 mL (500 mg/mL) Single Dose Glass Fliptop Vial
00409-2346-32	Dobutamine in 5% Dextrose Injection, USP 250 mg/250 mL (1 mg/mL) Flexible Container
00409-2347-32	Dobutamine in 5% Dextrose Injection, USP 500 mg/250 mL (2 mg/mL) Flexible Container
00409-3724-32	Dobutamine in 5% Dextrose Injection, USP 1,000 mg/250 mL (4 mg/mL) Flexible Container
00409-7809-22	Dopamine Hydrochloride in 5% Dextrose Injection, USP 400 mg/250 mL (1,600 mcg/mL) Flexible Container
00409-7810-22	Dopamine Hydrochloride in 5% Dextrose Injection, USP 800 mg/250 mL (3,200 mcg/mL) Flexible Container
00409-4933-01	Epinephrine Injection, USP 1 mg/10 mL (0.1 mg/mL) ABBOJECT™ Glass Syringe with Male Luer Lock Adapter and 20-Gauge protected needle
00409-9094-22	Fentanyl Citrate Injection, USP, CII 100 mcg/2 mL (50 mcg/mL) Single Dose Glass Fliptop Vial
00409-9093-35	Fentanyl Citrate Injection, USP, CII 250 mcg/5 mL (50 mcg/mL) Glass Ampoule
00409-7651-62	Heparin Sodium in 0.45% Sodium Chloride Injection, 12,500 USP Units/250 mL (50 USP Units/mL) Flexible Container
00409-7650-62	Heparin Sodium in 0.45% Sodium Chloride Injection, 25,000 USP Units/250 mL (100 USP Units/mL) Flexible Container
00409-3177-01	Lidocaine Hydrochloride and Epinephrine Injection 0.5%, USP (Lidocaine and Epinephrine 1:200,000) 250 mg/50 mL (5 mg/mL) Multiple Dose Glass Fliptop Vial
00409-3178-01	Lidocaine Hydrochloride and Epinephrine Injection 1%, USP (Lidocaine and Epinephrine 1:100,000) 200 mg/20 mL (10 mg/mL) Multiple Dose Glass Fliptop Vial
00409-3178-02	Lidocaine Hydrochloride and Epinephrine Injection 1%, USP (Lidocaine and Epinephrine 1:100,000) 300 mg/30 mL (10 mg/mL) Multiple Dose Glass Fliptop Vial
00409-3178-03	Lidocaine Hydrochloride and Epinephrine Injection 1%, USP (Lidocaine and Epinephrine 1:100,000) 500 mg/50 mL (10 mg/mL) Multiple Dose Glass Fliptop Vial
00409-3181-01	Lidocaine Hydrochloride and Epinephrine Injection 1.5%, USP (Lidocaine and Epinephrine 1:200,000) 450 mg/30 mL (15 mg/mL) Single Dose Glass Fliptop Vial
00409-1209-01	Lidocaine Hydrochloride 1.5% and Epinephrine Injection, USP (Lidocaine and Epinephrine 1:200,000) 75 mg/5 mL (15 mg/mL) Glass Ampoule
00409-3182-03	Lidocaine Hydrochloride and Epinephrine Injection 2%, USP (Lidocaine and Epinephrine 1:100,000) 1,000 mg/50 mL (20 mg/mL) Multiple Dose Glass Fliptop Vial
00409-3182-01	Lidocaine Hydrochloride and Epinephrine Injection 2%, USP (Lidocaine and Epinephrine 1:100,000) 400 mg/20 mL (20 mg/mL) Multiple Dose Glass Fliptop Vial
00409-3182-02	Lidocaine Hydrochloride and Epinephrine Injection 2%, USP (Lidocaine and Epinephrine 1:100,000) 600 mg/30 mL (20 mg/mL) Multiple Dose Glass Fliptop Vial
00409-3183-01	Lidocaine Hydrochloride and Epinephrine Injection 2%, USP (Lidocaine and Epinephrine 1:200,000) 400 mg/20 mL (20 mg/mL) Single Dose Glass Fliptop Vial
00409-9137-05	Lidocaine Hydrochloride Injection 1%, USP (For Cardiac Use Only) 50 mg/5 mL (10 mg/mL) ANSYR™ Plastic Syringe
00409-1323-05	Lidocaine Hydrochloride Injection 2%, USP (For Cardiac Use Only) 100 mg/5 mL (20 mg/mL) ANSYR™ Plastic Syringe
00409-4903-34	Lidocaine Hydrochloride Injection 2%, USP (For Cardiac Use Only) 100 mg/5 mL (20 mg/mL) LifeShield™ ABBOJECT™ Glass Syringe (20 G x 1 1/2")
00409-4277-02	Lidocaine Hydrochloride Injection 2%, USP 1,000 mg/50 mL (20 mg/mL) Multiple Dose Plastic Fliptop Vial
00409-4883-01	Linezolid Injection in 0.9% Sodium Chloride 600 mg/300 mL (2 mg/mL) VisIV™ Flexible Container
00409-6729-03	Magnesium Sulfate in Water for Injection 20 g/500 mL (40 mg/mL) Flexible Container
00409-4031-01	Mannitol Injection, USP 12.5 g/50 mL Single Dose Glass Fliptop Vial (25% concentration)
00409-2305-17	Midazolam Injection, USP CIV 2 mg/2mL (1 mg/mL) Single Dose Glass Fliptop Vial
00409-2308-02	Midazolam Injection, USP CIV 10 mg/2 mL (5 mg/mL) Single Dose Glass Fliptop Vial
00409-1134-03	Morphine Sulfate Injection, USP, CII (Preservative-Free and contains an antioxidant) 1,000 mg/20 mL (50 mg/mL) Single Dose Glass Fliptop Vial

NDC	Product Description
00409-1134-05	Morphine Sulfate Injection, USP, CII (Preservative-Free and contains an antioxidant) 2,500 mg/50 mL (50 mg/mL) Single Dose Glass Fliptop Vial
00409-1465-01	Nalbuphine Hydrochloride Injection 20 mg/mL Glass Ampoule
00409-1215-01	Naloxone Hydrochloride Injection, USP 0.4 mg/mL Single Dose Glass Fliptop Vial
00409-8183-01	Potassium Acetate Injection, USP 40 mEq/20 mL (2 mEq/mL) Single Dose Plastic Fliptop Vial
00409-6651-06	Potassium Chloride for Injection Concentrate, USP 20 mEq/10 mL (2 mEq/mL) Single Dose Plastic Fliptop Vial
00409-7295-01	Potassium Phosphates Injection, USP, 45 mM P/15 mL (3 mM P/mL) Single Dose Glass Fliptop Vial
00409-6629-02	Quelicin™ (succinylcholine chloride injection, USP) 200 mg/10 mL (20 mg/mL) Multiple Dose Glass Fliptop Vial
00409-9558-05	Rocuronium Bromide Injection 50 mg/5 mL (10 mg/mL) Multiple Dose Glass Fliptop Vial
00409-7299-73	Sodium Acetate Injection, USP 40 mEq/20 mL (2 mEq/mL) Single Dose Plastic Fliptop Vial
00409-3299-06	Sodium Acetate Injection, USP 200 mEq/100 mL (2 mEq/mL) Pharmacy Bulk Package Glass Fliptop Vial
00409-5534-14	4.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5 mEq/mL) ABBOJECT® Glass Syringe with Male Luer Lock Adapter and 20-Gauge protected needle
00409-5555-02	4.2% Sodium Bicarbonate Injection, USP 5 mL Fliptop Vial
00409-4916-14	7.5% Sodium Bicarbonate Injection, USP 44.6 mEq/50 mL (0.9 mEq/mL) LifeShield™ ABBOJECT™ Glass Syringe with Male Luer Lock Adapter and 18-Gauge protected needle
00409-6637-14	8.4% Sodium Bicarbonate Injection, USP 50 mEq/50 mL (1 mEq/mL) LifeShield® ABBOJECT® Glass Syringe Male Luer Lock Adapter and 18-Gauge protected needle
00409-1141-02	23.4% Sodium Chloride Injection, USP 400 mEq/100 mL (4 mEq/mL) Pharmacy Bulk Package Glass Fliptop Vial
00409-7391-72	Sodium Phosphates Injection, USP 45 mMol/15 mL (3 mMol P/mL) Single Dose Plastic Fliptop Vial
00409-5816-11	Sterile Empty Vial 10 mL Glass Bottle
00409-5816-31	Sterile Empty Vial 30 mL Glass Bottle
00409-9158-01	Vitamin K1 (phytonadione injectable emulsion, USP) 10 mg/mL Glass Ampoule

Appendix 2. Pfizer Hospital Rocky Mount Products available through Pfizer's emergency ordering process

NDC	Product Description
00409-1141-02	23.4% Sodium Chloride Injection, USP 400 mEq/100 mL (4 mEq/mL) Pharmacy Bulk Package Glass Fliptop Vial
00409-5555-02	4.2% Sodium Bicarbonate Injection, USP 5 mL Fliptop Vial
00409-6625-14	8.4% Sodium Bicarbonate Injection, USP 50 mEq/50 mL (1 mEq/mL) Single Dose Glass Fliptop Vial
00409-4910-34	Atropine Sulfate Injection, USP (Adult) 0.5 mg/5 mL LifeShield™ ABBOJECT™ Syringe
00409-4092-01	Copper (cupric chloride injection, USP) 4 mg/10 mL (0.4 mg/mL) Single Dose Plastic Fliptop Vial
00409-1775-10	Dextrose Injection 25%, USP (For Infant Use) 2.5 g/10 mL (250 mg/mL) ANSYR™ Plastic Syringe
00409-2344-01	Dobutamine Injection, USP 250 mg/20 mL (12.5 mg/mL) Single Dose Glass Fliptop Vial
00409-2344-02	Dobutamine Injection, USP 250 mg/20 mL (12.5 mg/mL) Single Dose Glass Fliptop Vial
00409-5820-01	Dopamine Hydrochloride Injection, USP 200 mg/5 mL (40 mg/mL) Single Dose Glass Fliptop Vial
00409-9104-20	Dopamine hydrochloride Injection, USP 400 mg/10 mL (40 mg/mL) Single Dose Glass Fliptop Vial
00409-3294-51	Potassium Acetate Injection, USP 100 mEq/50 mL (2 mEq/mL) Pharmacy Bulk Package Glass Fliptop Vial
00409-7295-01	Potassium Phosphates Injection, USP, 45 mM P/15 mL Single Dose Vial
00409-3299-05	Sodium Acetate Injection, USP 100 mEq/50 ml (2 mEq/mL) Pharmacy Bulk Package Glass Fliptop Vial
00409-9157-01	Vitamin K1 neonate (phytonadione injectable emulsion, USP) 1 mg/0.5 mL (2 mg/mL) Glass Ampoule

^a Emergency Ordering process:

- Emergency orders should be placed through customers' Pfizer Hospital representative or account executive. If the representative is unknown, emergency orders may be placed via the Pfizer Hospital Supply Continuity Team, available between 7 am and 5 pm CST at 1-844-646-4398 (select option 1, then option 3).
- Customers will be asked to provide a requested order quantity and average monthly demand/usage.
- Orders will be reviewed and released in the order received and based on available inventory. The cut off time for overnight requests is 12 pm CST, and shipments will not occur on Sundays. Customers may not receive the full requested amount.
- The representative will keep providers apprised of the fulfillment status of the order.
- Prior to making an emergency request, customers are encouraged to check availability through their wholesaler to obtain product or use appropriate therapeutic alternatives.

Additional resources

Supply assurance webpage; Vizient Newsroom; Vizient Drug Shortage Alerts; Mitigation Strategy Library; Vizient Essential Medications



Want to receive weekly Supply Assurance updates?

Update your preferences through our [Subscription Manager](#) by selecting Supply Assurance Weekly Digest.

Questions? Contact disasterresponse@vizientinc.com, pharmacyquestions@vizientinc.com, novaplus@vizientinc.com